David Raben is Chief Medical Officer at Bicara Therapeutics Inc. (BCAX). They have made 1 open-market trade across 1 company since 2025, most recently 2026-04-27.
CIK 0002034679
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BCAX | 55,286 | $927K |
Shares reported on the most recent Form 4, priced at the 2026-04-28 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BCAX | SELL · 10b5-1 | 2026-04-27 | 2026-04-28 | $22.88 | $126K | +5.2% | +1.5% | +29.5% |
| BCAX | SELL · 10b5-1 | 2026-03-25 | 2026-03-26 | $18.95 | $208K | +15.9% | +20.5% | +37.5% |
| BCAX | SELL | 2026-03-03 | 2026-03-05 | $18.52 | $306K | +5.9% | +14.2% | +9.5% |
| BCAX | SELL · 10b5-1 | 2025-11-24 | 2025-11-25 | $18.70 | $292K | +2.7% | -8.7% | -10.9% |
| BCAX | SELL · 10b5-1 | 2025-10-09 | 2025-10-10 | $18.45 | $406K | -11.3% | -24.9% | -10.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.